Literature DB >> 25806311

Lung cancer molecular epidemiology in China: recent trends.

Caicun Zhou1.   

Abstract

Lung cancer is both the most common diagnosed cancer and the leading cause of cancer related deaths in China. During the past three decades, the incidence and mortality of lung cancer in China are increasing rapidly. According to data from National Central Cancer Registry (NCCR) in 2010, the crude incidence of lung cancer in China was 46.08 per 100,000 population (61.86 per 100,000 men and 29.54 per 100,000 women), with an estimated over 600,000 new diagnosed lung cancer patients (416,333 males and 189,613 females). Meanwhile, the crude mortality of lung cancer in China was 37.00 per 100,000 population (50.04 per 100,000 men and 23.33 per 100,000 women). Consistent with the change in developed countries, adenocarcinoma has become the most predominant histological subtype of lung cancer in China. For the majority advanced non-small-cell lung cancer (NSCLC) patients, especially patients with adenocarcinoma, targeted therapy became increasing important in the treatment. Chinese researcher have done a lot work in terms of lung cancer molecular epidemiology, therefore, in this review, we further summarized the epidemiology of driver genes in NSCLC, hoping to help clinicians to better screen certain driver genes in China for treatment decisions.

Entities:  

Keywords:  Lung cancer; incidence; molecular epidemiology; mortality

Year:  2014        PMID: 25806311      PMCID: PMC4367759          DOI: 10.3978/j.issn.2218-6751.2014.09.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  87 in total

1.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

2.  [Incidence trends and pathological characteristics of lung cancer in urban Beijing during period of 1998 - 2007].

Authors:  Ning Wang; Wan-qing Chen; Wei-xing Zhu; Xiu-mei Xing; Ai-ping Lu; Lei Yang
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2011-03

3.  Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking.

Authors:  S D Stellman; J E Muscat; S Thompson; D Hoffmann; E L Wynder
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

4.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

5.  Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Authors:  Hang Li; Yunjian Pan; Yuan Li; Chenguang Li; Rui Wang; Haichuan Hu; Yang Zhang; Ting Ye; Lei Wang; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Lung Cancer       Date:  2012-10-23       Impact factor: 5.705

6.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

7.  Cigarette smoking and changes in the histopathology of lung cancer.

Authors:  M J Thun; C A Lally; J T Flannery; E E Calle; W D Flanders; C W Heath
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

8.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

Authors:  Yunjian Pan; Yang Zhang; Yuan Li; Haichuan Hu; Lei Wang; Hang Li; Rui Wang; Ting Ye; Xiaoyang Luo; Yiliang Zhang; Bin Li; Deng Cai; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Lung Cancer       Date:  2014-02-19       Impact factor: 5.705

Review 9.  Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.

Authors:  Liang Fan; Yun Feng; Huanying Wan; Guochao Shi; Wenquan Niu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

10.  Trends in lung cancer incidence by histological type in Osaka, Japan.

Authors:  Yasuhiro Toyoda; Tomio Nakayama; Akiko Ioka; Hideaki Tsukuma
Journal:  Jpn J Clin Oncol       Date:  2008-08-09       Impact factor: 3.019

View more
  58 in total

1.  Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.

Authors:  Wentao Li; Jichen Qu; Zhifei Xu
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

2.  CYP1A2 rs2069514 polymorphism and lung cancer susceptibility: a meta-analysis.

Authors:  Wenlong Shao; Jianxing He
Journal:  Ann Transl Med       Date:  2015-05

3.  [Primary lung cancer in Chinese renal transplant recipients: a single-center analysis].

Authors:  Shu-Xin Zhang; Yang Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-06-20

4.  Functional analysis of CD14+HLA-DR-/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma.

Authors:  Yun Chen; Guichang Pan; Dongbo Tian; Yifei Zhang; Taoping Li
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

5.  MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway.

Authors:  Qing Wang; Feng Geng; Haomin Zhou; Yecheng Chen; Juan Du; Xinyu Zhang; Dandan Song; Hongwen Zhao
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

6.  The role of SOX-2 on the survival of patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

7.  Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Lihong Ma; Ping Zhan; Yafang Liu; Zejun Zhou; Qingqing Zhu; Yingying Miu; Xiaoxia Wang; Jiajia Jin; Qian Li; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-04

8.  Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.

Authors:  Jinping Fan; Haiying Yu; Ying Lv; Liguo Yin
Journal:  Tumour Biol       Date:  2015-09-03

9.  MicroRNA-374b inhibits the tumor growth and promotes apoptosis in non-small cell lung cancer tissue through the p38/ERK signaling pathway by targeting JAM-2.

Authors:  Yujun Wang; Lijuan Yu; Tao Wang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

10.  Human umbilical vein endothelial cells-derived microRNA-203-containing extracellular vesicles alleviate non-small-cell lung cancer progression through modulating the DTL/p21 axis.

Authors:  Tiangang Ma; Yanbing Hu; Yinxue Guo; Qinghua Zhang
Journal:  Cancer Gene Ther       Date:  2021-02-08       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.